Loss of heterozygosity for chromosomes 16q in Wilms tumors predicts outcomes: A meta-analysis

ARTICLE HIGHLIGHTS

Research background

Wilms tumor (WT) is a prevalent childhood disease with variable treatment outcomes, primarily attributed to multi-gene mutations. Ongoing research has identified 16q loss of heterozygosity (LOH) as a site deletion linked to a poor prognosis.

Research motivation

The aim is to elucidate the relationship between 16q LOH and WT, providing effective guidance for the clinical treatment of this disease.

Research objectives

The primary objective is to determine whether 16q LOH can serve as a predictive marker for a dismal prognosis in patients with WT, utilizing statistical analysis.

Research methods

The primary objective is to determine whether 16q LOH can serve as a predictive marker for a dismal prognosis in patients with WT, utilizing statistical analysis.

Research results

Eleven cohort studies were evaluated to estimate the relationship between event-free survival and 16q LOH in patients with WT (I² = 25%, P < 0.001). As expected, 16q LOH emerged as a reliable predictor of event-free survival in patients with WT (risk ratio = 1.95, 95%CI: 1.52–2.49, P < 0.001).

Research conclusions

In pediatric patients with WT, a discernible correlation exists between 16q LOH and an unfavorable treatment prognosis. The clinical detection of chromosome 16q LOH warrants increased attention to the patient’s prognosis.

Research perspectives

Genetic mutations in the 16q LOH locus are indicative of a poor prognosis in patients with WT. However, to establish a clearer relationship between the two factors, conclusive results necessitate a larger sample size, incorporating randomized controlled trial research combined with meta-analysis.